Research Analysts’ Recent Ratings Updates for Abbott Laboratories (ABT)

A number of firms have modified their ratings and price targets on shares of Abbott Laboratories (NYSE: ABT) recently:

• 1/23/2026 – Abbott Laboratories had its price target lowered by analysts at Citigroup Inc. from $155.00 to $140.00. They now have a “buy” rating on the stock.
• 1/23/2026 – Abbott Laboratories had its price target lowered by analysts at Sanford C. Bernstein from $154.00 to $125.00. They now have an “outperform” rating on the stock.
• 1/23/2026 – Abbott Laboratories had its price target lowered by analysts at Royal Bank Of Canada from $147.00 to $135.00. They now have an “outperform” rating on the stock.
• 1/23/2026 – Abbott Laboratories had its price target lowered by analysts at Raymond James Financial, Inc. from $146.00 to $130.00. They now have an “outperform” rating on the stock.
• 1/23/2026 – Abbott Laboratories had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $152.00 to $140.00. They now have a “buy” rating on the stock.
• 1/23/2026 – Abbott Laboratories had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $140.00 to $132.00. They now have an “outperform” rating on the stock.
• 1/23/2026 – Abbott Laboratories had its price target lowered by analysts at Evercore ISI from $144.00 to $138.00. They now have an “outperform” rating on the stock.
• 1/23/2026 – Abbott Laboratories had its price target lowered by analysts at Piper Sandler from $150.00 to $135.00. They now have an “overweight” rating on the stock.
• 1/23/2026 – Abbott Laboratories had its price target lowered by analysts at BTIG Research from $145.00 to $140.00. They now have a “buy” rating on the stock.
• 1/9/2026 – Abbott Laboratories had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $157.00 to $152.00. They now have a “buy” rating on the stock.
• 1/9/2026 – Abbott Laboratories had its price target raised by analysts at Sanford C. Bernstein from $150.00 to $154.00. They now have an “outperform” rating on the stock.
• 1/5/2026 – Abbott Laboratories had its price target raised by analysts at Evercore ISI from $142.00 to $144.00. They now have an “outperform” rating on the stock.
• 1/5/2026 – Abbott Laboratories had its price target raised by analysts at Barclays PLC from $162.00 to $169.00. They now have an “overweight” rating on the stock.
• 12/29/2025 – Abbott Laboratories had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Abbott Laboratories had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Abbott Laboratories had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Abbott Laboratories had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.